Brief: Zynerba Pharmaceuticals Presents Positive Data From Phase 2 Inspire Trial In 22Q11.2 Deletion Syndrome At The National Organization For Rare Disorders (Nord) Rare Diseases And Orphan Products Breakthrough Summit

Zynerba Pharmaceuticals

17/10/2022 12:14

Oct 17 (Reuters) - Zynerba Pharmaceuticals Inc  ZYNE.O :
    * ZYNERBA PHARMACEUTICALS PRESENTS POSITIVE DATA FROM PHASE
2
INSPIRE TRIAL IN 22Q11.2 DELETION SYNDROME AT THE NATIONAL
ORGANIZATION FOR RARE DISORDERS (NORD) RARE DISEASES AND ORPHAN
PRODUCTS BREAKTHROUGH SUMMIT
    * ZYNERBA PHARMACEUTICALS INC- THREE PATIENTS REPORTED
TREATMENT
RELATED ADVERSE EVENTS WHICH WERE ALL MILD APPLICATION SITE
ADVERSE EVENTS
    * ZYNERBA PHARMACEUTICALS INC- ONE PATIENT DISCONTINUED
TREATMENT
DUE TO ADVERSE EVENTS NOT RELATED TO ZYGEL

Source text for Eikon:  ID:nGNX3NBvl9 
Further company coverage:  ZYNE.O 
 ((Reuters.Briefs@thomsonreuters.com;;))